LUND, SWEDEN--(Marketwire - January 03, 2013) - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the JP Morgan 31st Annual Healthcare Conference
held
January 6-10, 2013 in San Francisco, US. During the presentation, an update
regarding Active Biotech's development programs will be provided.

The presentation will include the laquinimod MS project, a novel oral
immunomodulatory drug for the treatment of multiple sclerosis, licensed to
Teva
Pharmaceutical Industries Ltd, the Phase III prostate cancer project TASQ
in
co-development with Ipsen, as well as ANYARA, Active Biotech's novel
concept for
tumor therapy in a Phase III study for renal cell cancer. Also, the project
57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed
via
the Active Biotech web site. To access the live and replay presentations
please
go to - www.activebiotech.com.

The presentation will take place on January 10, at 8:00 am PST (Pacific
Standard
Time) / 17.00 Central European Time.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or
entering
pivotal phase are laquinimod, an orally administered small molecule with
unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
for
prostate cancer as well as ANYARA for use in cancer targeted therapy,
primarily
of renal cell cancer. In addition, laquinimod is in Phase II development
for
Crohn's and Lupus. An additional project in clinical development is the
orally
administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.

Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 10:00 a.m. CET on January 3, 2013.